Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
19.3M
-
Number of holders
-
256
-
Total 13F shares, excl. options
-
18.7M
-
Shares change
-
+444K
-
Total reported value, excl. options
-
$1.97B
-
Value change
-
+$46.5M
-
Put/Call ratio
-
0.86
-
Number of buys
-
129
-
Number of sells
-
-112
-
Price
-
$105.14
Significant Holders of LIGAND PHARMACEUTICALS INC - Common Stock (LGND) as of Q1 2025
292 filings reported holding LGND - LIGAND PHARMACEUTICALS INC - Common Stock as of Q1 2025.
LIGAND PHARMACEUTICALS INC - Common Stock (LGND) has 256 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 18.7M shares
of 19.3M outstanding shares and own 96.83% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (2.92M shares), VANGUARD GROUP INC (2.06M shares), JANUS HENDERSON GROUP PLC (1.03M shares), MACQUARIE GROUP LTD (906K shares), DIMENSIONAL FUND ADVISORS LP (745K shares), STATE STREET CORP (727K shares), CONGRESS ASSET MANAGEMENT CO (643K shares), Stephens Investment Management Group LLC (607K shares), Chicago Capital, LLC (555K shares), and GEODE CAPITAL MANAGEMENT, LLC (464K shares).
This table shows the top 256 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.